Subramanian Sanjay

CIK 00017902462 companiesBOSTON, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001790246

Recent Transactions

46 trades

Disposition to Issuer
Inozyme Pharma, Inc.
Stock Option (Right to Buy)
2025-07-01−135,000→ 0 total
Disposition to Issuer
Inozyme Pharma, Inc.
Restricted Stock Units
2025-07-01−38,500→ 0 total
Disposition to Issuer
Inozyme Pharma, Inc.
Stock Option (Right to Buy)
2025-07-01−145,000→ 0 total
Disposition from Tender
Inozyme Pharma, Inc.
Common Stock
2025-07-01$4.00/sh−39,701→ 0 total
Disposition to Issuer
Inozyme Pharma, Inc.
Stock Option (Right to Buy)
2025-07-01−180,000→ 0 total
Award
Inozyme Pharma, Inc.
Common Stock
2025-06-25$0.74/sh+6,813→ 39,701 total
Award
Inozyme Pharma, Inc.
Common Stock
2025-03-31$0.77/sh+2,490→ 32,888 total
Award
Inozyme Pharma, Inc.
Restricted Stock Units
2025-03-11+38,500→ 38,500 total
Award
Inozyme Pharma, Inc.
Stock Option (right to buy)
2025-03-11+145,000→ 145,000 total
Award
Inozyme Pharma, Inc.
Stock Option (right to buy)
2024-03-13+165,000→ 165,000 total
Award
Inozyme Pharma, Inc.
Common Stock
2023-09-29$3.57/sh+2,319→ 30,398 total
Award
Inozyme Pharma, Inc.
Common Stock
2023-03-31$2.21/sh+979→ 28,079 total
Award
Inozyme Pharma, Inc.
Stock option (right to buy)
2023-03-23+135,000→ 135,000 total
Purchase
Inozyme Pharma, Inc.
Common Stock
2022-04-19$3.69/sh+27,100→ 27,100 total
Award
Inozyme Pharma, Inc.
Stock option (right to buy)
2022-03-21+180,000→ 180,000 total
Award
Ocugen, Inc.$OCGN
Stock Option (Right to Buy)
2022-01-03+454,007→ 454,007 total
Award
Ocugen, Inc.$OCGN
Common Stock
2022-01-03+125,534→ 161,125 total
Award
Ocugen, Inc.$OCGN
Option(Right toBuy)
2021-12-16+35,560→ 71,120 total
Award
Ocugen, Inc.$OCGN
Option (Right to Buy)
2021-11-16+35,560→ 35,560 total
Sale
Ocugen, Inc.$OCGN
Common Stock
2021-10-26$11.07/sh−10,000→ 35,591 total
Exercise/Conversion
Ocugen, Inc.$OCGN
Option (Right to Buy)
2021-10-15−7,990→ 7,990 total
Sale
Ocugen, Inc.$OCGN
Common Stock
2021-10-15$9.96/sh−7,990→ 45,591 total
Exercise/Conversion
Ocugen, Inc.$OCGN
Common Stock
2021-10-15$2.19/sh+7,990→ 53,581 total
Sale
Ocugen, Inc.$OCGN
Common Stock
2021-08-16$7.22/sh−30,000→ 45,591 total
Exercise/Conversion
Ocugen, Inc.$OCGN
Common Stock
2021-08-16$0.34/sh+30,000→ 75,591 total
Exercise/Conversion
Ocugen, Inc.$OCGN
Option (Right to Buy)
2021-08-16−30,000→ 246,170 total
Exercise/Conversion
Ocugen, Inc.$OCGN
Common Stock
2021-07-15$0.34/sh+31,086→ 76,677 total
Exercise/Conversion
Ocugen, Inc.$OCGN
Options (Right to Buy)
2021-07-15−31,086→ 276,170 total
Sale
Ocugen, Inc.$OCGN
Common Stock
2021-07-15$6.70/sh−31,086→ 45,591 total
Sale
Ocugen, Inc.$OCGN
Common Stock
2021-06-15$7.00/sh−31,000→ 45,591 total
Exercise/Conversion
Ocugen, Inc.$OCGN
Common Stock
2021-06-15$0.34/sh+31,000→ 76,591 total
Exercise/Conversion
Ocugen, Inc.$OCGN
Option (Right to Buy)
2021-06-15−31,000→ 307,256 total
Exercise/Conversion
Ocugen, Inc.$OCGN
Option (Right to Buy)
2021-05-14−31,000→ 338,256 total
Sale
Ocugen, Inc.$OCGN
Common Stock
2021-05-14$8.18/sh−31,000→ 45,591 total
Exercise/Conversion
Ocugen, Inc.$OCGN
Common Stock
2021-05-14$0.34/sh+31,000→ 76,591 total
Exercise/Conversion
Ocugen, Inc.$OCGN
Common Stock
2021-04-29$2.19/sh+7,990→ 53,581 total
Exercise/Conversion
Ocugen, Inc.$OCGN
Option (Right to Buy)
2021-04-29−7,990→ 15,980 total
Sale
Ocugen, Inc.$OCGN
Common Stock
2021-04-29$10.98/sh−7,990→ 45,591 total
Exercise/Conversion
Ocugen, Inc.$OCGN
Option (Right to Buy)
2021-01-29−35,591→ 71,183 total
Exercise/Conversion
Ocugen, Inc.$OCGN
Common Stock
2021-01-29$0.51/sh+35,591→ 45,591 total
Award
Ocugen, Inc.$OCGN
Option (Right to Buy)
2021-01-01+800,000→ 800,000 total
Award
Ocugen, Inc.$OCGN
Options (Right to Buy)
2020-05-05+369,256→ 369,256 total
Award
Ocugen, Inc.$OCGN
Options (Right to Buy)
2020-01-02+106,774→ 106,774 total
Purchase
Ocugen, Inc.$OCGN
Common Stock
2019-11-22$0.28/sh+5,000→ 10,000 total
Purchase
Ocugen, Inc.$OCGN
Common Stock
2019-10-02$1.88/sh+5,000→ 5,000 total
Award
Ocugen, Inc.$OCGN
Stock Options
2019-10-01+23,970→ 23,970 total

Companies

Recent Filings

Address

C/O INOZYME PHARMA, INC. 321 SUMMER STREET SUITE 400

BOSTON, MA, 02210

View on SEC.gov